Literature DB >> 24839218

Ezetimibe treatment should be considered for patients with sitosterolemia.

Miao Hu1, Brian Tomlinson.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24839218     DOI： 10.1007/s00467-014-2843-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.

Authors:  André J Tremblay; Benoît Lamarche; Valéry Lemelin; Lizbeth Hoos; Suzanne Benjannet; Nabil G Seidah; Harry R Davis; Patrick Couture
Journal:  J Lipid Res       Date:  2010-12-01       Impact factor: 5.922

Review 2.  Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism.

Authors:  Kazumi Tsubakio-Yamamoto; Makoto Nishida; Yumiko Nakagawa-Toyama; Daisaku Masuda; Tohru Ohama; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2010-06-11       Impact factor: 4.928

3.  Atherosclerotic renal artery stenosis as a cause for hypertension in an adolescent patient.

Authors:  Tennille N Webb; Mohun Ramratnam; Rhobert W Evans; Trevor Orchard; John Pacella; Elif Erkan
Journal:  Pediatr Nephrol       Date:  2014-02-16       Impact factor: 3.714
  3 in total
  2 in total

1.  Rebuttal to "ezetimibe treatment should be considered for patients with sitosterolemia".

Authors:  Elif Erkan
Journal:  Pediatr Nephrol       Date:  2014-05-17       Impact factor: 3.714

2.  Sitosterolemia: Four Cases of an Uncommon Cause of Hemolytic Anemia (Mediterranean Stomatocytosis with Macrothrombocytopenia).

Authors:  Sudhamsh Reddy Desai; Anu Korula; Uday Prakash Kulkarni; Aswathy Ashok Menon; Shaji V Ramachandran; Eunice Sindhuvi; Arun Jose Nellickal; Sukesh C Nair; Biju George
Journal:  Indian J Hematol Blood Transfus       Date:  2020-10-22       Impact factor: 0.900
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.